Molecular diagnostics in chronic lymphocytic leukemia - pathogenetic and clinical implications

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Rai and Binet staging systems are standard for chronic lymphocytic leukemia (CLL) but show significant patient heterogeneity.
• Molecular and cellular markers are increasingly used to predict CLL prognosis.
• Variable region of the Ig heavy chain (VH) mutation status and genomic aberrations define distinct CLL subgroups.

Purpose of the Study:

• To highlight the importance of molecular and cellular markers in predicting CLL prognosis.
• To discuss the role of VH status and genomic aberrations in classifying CLL.
• To review the utility of FISH and other genomic analysis techniques in CLL.

Main Methods:

• Fluorescence in situ hybridization (FISH) to detect genomic aberrations in ~80% of CLL cases.
• Other methods like array-CGH, SNP-arrays, and cytogenetics to assess all chromosomal regions.
• Analysis of VH mutation status and common genomic aberrations (13q, 11q, 17p deletions, trisomy 12).

Main Results:

• Genomic aberrations subdivide CLL into distinct clinical subgroups.
• Frequent aberrations include deletions in 13q, 11q, 17p, and trisomy 12.
• Deletions 11q and 17p are linked to rapid progression and poorer survival, identifying patients for specific treatments.

Conclusions:

• Genomic aberrations provide insights into CLL pathogenesis and identify subgroups with distinct clinical features.
• Patients with 11q- or 17p- CLL benefit from alternative treatments or stem cell transplantation.
• Favorable genetic abnormalities may allow for de-escalation of current treatment approaches.